These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36128333)

  • 1. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa.
    Zar HJ; MacGinty R; Workman L; Botha M; Johnson M; Hunt A; Burd T; Nicol MP; Flasche S; Quilty BJ; Goldblatt D
    EClinicalMedicine; 2022 Nov; 53():101655. PubMed ID: 36128333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Madhi SA; Kwatra G; Richardson SI; Koen AL; Baillie V; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Aley PK; Bhikha S; Bhorat AE; Esmail A; Horne E; Kaldine H; Mukendi CK; Madzorera VS; Manamela NP; Masilela M; Hermanus ST; Motlou T; Mzindle N; Oelofse S; Patel F; Rhead S; Rossouw L; Taoushanis C; van Eck S; Lambe T; Gilbert SC; Pollard AJ; Moore PL; Izu A
    Lancet Infect Dis; 2023 Mar; 23(3):295-306. PubMed ID: 36273491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals.
    Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F
    BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients.
    Gonçalves BP; Hall M; Jassat W; Balan V; Murthy S; Kartsonaki C; Semple MG; Rojek A; Baruch J; Reyes LF; Dasgupta A; Dunning J; Citarella BW; Pritchard M; Martín-Quiros A; Sili U; Baillie JK; Aryal D; Arabi Y; Rashan A; Angheben A; Caoili J; Carrier FM; Harrison EM; Gómez-Junyent J; Figueiredo-Mello C; Douglas JJ; Mat Nor MB; Chow YP; Wong XC; Bertagnolio S; Thwin SS; Streinu-Cercel A; Salazar L; Rishu A; Rangappa R; Ong DSY; Hashmi M; Carson G; Diaz J; Fowler R; Kraemer MUG; Wils EJ; Horby P; Merson L; Olliaro PL;
    Elife; 2022 Oct; 11():. PubMed ID: 36197074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
    Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
    EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
    Molteni E; Canas LS; Kläser K; Deng J; Bhopal SS; Hughes RC; Chen L; Murray B; Kerfoot E; Antonelli M; Sudre CH; Pujol JC; Polidori L; May A; Hammers PA; Wolf J; Spector PTD; Steves CJ; Ourselin PS; Absoud M; Modat M; Duncan PEL
    Lancet Reg Health Eur; 2022 Aug; 19():100429. PubMed ID: 35821715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends of humoral immune responses to heterologous antigenic exposure due to vaccination & omicron SARS-CoV-2 infection: Implications for boosting.
    Batra G; Murugesan DR; Raghavan S; Chattopadhyay S; Mehdi F; Ayushi ; Gosain M; Singh S; Das SJ; Deshpande S; Sonar S; Jakhar K; Bhattacharya J; Mani S; Pandey AK; Sankalp ; Goswami S; Das A; Dwivedi T; Sharma N; Kumar S; Sharma P; Kapoor S; Kshetrapa P; Wadhwa N; Thiruvengadam R; Kumar R; Gupta R; Garg PK; Bhatnagar S
    Indian J Med Res; 2023 Jun; 157(6):509-518. PubMed ID: 37322634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
    Liew F; Talwar S; Cross A; Willett BJ; Scott S; Logan N; Siggins MK; Swieboda D; Sidhu JK; Efstathiou C; Moore SC; Davis C; Mohamed N; Nunag J; King C; Thompson AAR; Rowland-Jones SL; Docherty AB; Chalmers JD; Ho LP; Horsley A; Raman B; Poinasamy K; Marks M; Kon OM; Howard L; Wootton DG; Dunachie S; Quint JK; Evans RA; Wain LV; Fontanella S; de Silva TI; Ho A; Harrison E; Baillie JK; Semple MG; Brightling C; Thwaites RS; Turtle L; Openshaw PJM; ;
    EBioMedicine; 2023 Jan; 87():104402. PubMed ID: 36543718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phylogenomic early warning signals for SARS-CoV-2 epidemic waves.
    Drake KO; Boyd O; Franceschi VB; Colquhoun RM; Ellaby NAF; Volz EM
    EBioMedicine; 2024 Feb; 100():104939. PubMed ID: 38194742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal and Cord Anti-SARS-CoV-2-Spike IgG following COVID-19 Vaccination versus Infection during Pregnancy: A Prospective Study, Israel October 2021-March 2022.
    Abu Shqara R; Frank Wolf M; Mikhail Mustafa S; Sgayer I; Assulyn T; Abu Zraki A; Askhar Majadla N; Rechnizter H; Shehadeh M; Fleisher Sheffer V; Bordeynik-Cohen M; Yakir O; Lowenstein L; Sela E; Edelstein M; Dror AA
    Am J Perinatol; 2024 May; 41(S 01):e1935-e1943. PubMed ID: 37164317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
    Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Jan; ():. PubMed ID: 35118480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis.
    COVID-19 Forecasting Team
    Lancet; 2023 Mar; 401(10379):833-842. PubMed ID: 36930674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.